About IndiDX
IndiDX is a company based in Boulder (United States) founded in 2005 was acquired by Biodesix in July 2018. IndiDX has raised $82.81 million across 6 funding rounds from investors including Biodesix, Baird Capital and InterWest. The company has 17 employees as of December 31, 2017. IndiDX operates in a competitive market with competitors including Oncimmune, Biodesix, Broncus, OncoCyte and Riverain Tech, among others.
- Headquarter Boulder, United States
- Employees 17 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Integrated Diagnostics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of IndiDX
IndiDX has successfully raised a total of $82.81M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $6.1 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IndiDX
IndiDX has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Biodesix, Baird Capital and InterWest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity and venture capital investments in B2B Tech & Services companies.
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for IndiDX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IndiDX
Investment portfolio details for IndiDX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IndiDX
Detailed financials for IndiDX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indidx Comparisons
Peer comparison for IndiDX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IndiDX
IndiDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, Broncus, OncoCyte and Riverain Tech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Minimally invasive technologies for lung disease treatment are developed.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Software tools are developed for early lung disease detection.
|
|
| Locked | Locked | Locked |
Developer of diagnostic product for colon cancer
|
Detailed competitors of IndiDX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indidx
Complete news archive for IndiDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IndiDX
IndiDX was founded in 2005.
IndiDX is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
IndiDX is a funded company, having raised a total of $82.81M across 6 funding rounds to date.
As of Dec 31, 2017, the latest employee count at IndiDX is 17.
Integrated Diagnostics (Indi) is developing blood based diagnostics for oncology by following a systems biology based approach. Its flagship product, the Xpresys Lung test claims to detect the molecular changes in proteins associated with the presence of lung cancer and provide a non-invasive assessment of pulmonary nodules. Patient blood is analyzed by mass spectrometry that provides specific detection of target proteins. When combined with clinical assessment, Xpresys Lung claims to be able to help reduce unnecessary invasive procedures.
IndiDX has 7 investors. Key investors include Biodesix, Baird Capital, InterWest, Wellcome, and Life Sciences Alternative Funding.